Where can I learn more about this study?
You can find more information about this study on the websites listed below. When a full report
of the study results is available, it also can be found here.
X www.clinicaltrials.gov. Once you are on the website, type “NCT03084471”
into the search box and click “Search”.
X http://www.clinicaltrialsregister.eu. Once you are on the website, click “Home and
Search”, then type “2016-005068-33” in the search box and click “Search”.
X www.AstraZenecaClinicalTrials.com. Once you are on the website, type “D4191C00068”
into the search box, and click “Find a Study”.
Full Study Title: An Open-Label, Multi-Center, Safety Study of Fixed-Dose Durvalumab
+ Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid
Malignancies (STRONG) Module A – Post-Chemotherapy Urothelial and NonUrothelial
Carcinoma of the Urinary Tract with Fixed-dose Durvalumab
AstraZeneca Protocol Number: D4191C00068
National Clinical Trials Number: NCT03084471
EudraCT Number: 2016-005068-33
AstraZeneca sponsored this study and has its headquarters in Cambridge, UK.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical study participants belong to a large community of people who take part in
clinical research around the world. They help researchers answer important
health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused on
educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants
for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2021_11_17
12 | Clinical Study Results